[Skip to Content]
[Skip to Content Landing]
July 1993

Clinical Immunoscintigraphy of Recurrent Ovarian Cancer With Indium 111–Labeled B72.3 Monoclonal Antibody

Author Affiliations

From the Department of Surgery, University of California—Davis Medical Center, Sacramento. Dr Krag is now with the Department of Surgery, University of Vermont, and University Surgical Associates, Burlington, Vt.

Arch Surg. 1993;128(7):819-823. doi:10.1001/archsurg.1993.01420190115015

Objective:  To prospectively evaluate the ability for immunoscintigraphy with monoclonal antibody CYT-103 labeled with indium 111 to detect tumor presence in 15 patients with ovarian cancer undergoing second-look surgery.

Design:  Prospective, open-label, nonrandomized trial.

Setting:  Hospital-based nuclear medicine facility and operating room.

Study Participants:  Patients with previous ovarian cancer scheduled for second-look surgery.

Main Outcome Measure:  Correctness of prediction of immunoscintigraphy for presence or absence of ovarian cancer compared with serum CA 125 titer and computed tomography.

Results:  Immunoscintigraphy, computed tomography, and serum CA 125 titer had respective sensitivities of 92%, 42%, and 42%; specificities of 67%, 100%, and 100%; accuracies of 87%, 53%, and 53%; and diagnostic values of 59%, 42%, and 42%. The full regional extent of recurrent tumor was correctly detected in 45% of patients by immunoscintigraphy and in none of the patients by computed tomography. Immunoscintigraphy detected miliary tumor in two of four patients and computed tomography, as expected, was unable to detect miliary disease.

Conclusions:  Recurrent ovarian cancer often presents as multiple small lesions throughout the abdominal cavity. In this subset of patients, immunoscintigraphy may be particularly well suited for detection of the presence of recurrent tumor.(Arch Surg. 1993;128:819-823)